ClinicalTrials.gg

Program

beruzatatug pelitecan

Also written as “YL202”, “BNT326” and “YL202 should be intravenously infused”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Melanoma, led by 2 companies.

Furthest: phase 3, since Feb 10, 20269 company-led studies, 9 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MediLink Therapeutics (Suzhou)77 open or runningphase 3since Feb 10, 2026Dec 1, 2022Nov 2026phase 2 · NCT06107686
BioNTech22 open or runningphase 2since Jul 3, 2025Jul 3, 2025Mar 2028phase 2 · NCT07070232

Also a collaborator on its studies: BioNTech (Shanghai) Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2022First study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT05653752 · 80 enrolled · United States, China
  2. Oct 20, 2023Phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06107686 · 200 planned · China
  3. May 16, 2024Phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06439771 · 180 planned · China
  4. Jul 3, 2025BioNTech’s first study: phase 2 study in Lethal Congenital Contracture Syndrome 2New to BioNTechBioNTech · NCT07070232 · 1,438 planned · United States, Australia, Belgium and more
  5. Aug 1, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungBioNTech · NCT07111520 · 880 planned · United States, Australia, China and more
  6. Sep 3, 20252 phase 2 studiesMediLink Therapeutics (Suzhou) · NCT07169994, NCT07202364
  7. Feb 10, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedMediLink Therapeutics (Suzhou) · NCT07416994 · 440 planned · China
  8. Mar 4, 2026Phase 3 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT07461454 · 376 planned · China
  9. Oct 14, 2026Primary completion moved from 2026-07-30 to 2027-07-30Date moved laterphase 2 · +12 months · NCT06439771
  10. Oct 14, 2026Primary completion moved from 2026-08-31 to 2027-01-31Date moved laterphase 2 · +5 months · NCT07202364

Ahead

  1. Nov 2026Primary completion: phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06107686
  2. Dec 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT05653752
  3. Jan 31, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungMediLink Therapeutics (Suzhou) · NCT07202364
  4. Jul 30, 2027Primary completion: phase 2 study in Breast NeoplasmsMediLink Therapeutics (Suzhou) · NCT06439771

TargetBeta

ERBB3 →read by rule
“An antibody-drug conjugate (ADC) composed of beruzatatug, an immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) ”NCIt, by rule

Other programs on ERBB3

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
patritumab deruxtecanMerckphase 317
ruzaltatug rezetecanJiangsu HengRui Medicinephase 38
JSKN016ruleAlphamab Oncologyphase 35
SYS6023ruleCSPC Pharmaceutical Groupphase 22
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002rulexadcera-biopharmaceutical-suzhou-co-ltdphase 21
Anti-HER3/Exatecan Antibody-drug Conjugate ENV-501rulehummingbird-biosciencephase 21
Anti-EGFR/Anti-HER3 Bispecific Antibody-drug Conjugate AVZO-1418ruleavenzo-therapeutics-incphase 21
KHN922ruleChengdu Kanghong Pharmaceutical Groupphase 21
CS5007ruleCStone Pharmaceuticalsphase 11
JSKN016HCruleAlphamab Oncologyphase 11

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07461454Breast Neoplasms · China3RecruitingMediLink Therapeutics (Suzhou)Dec 31, 2027376
NCT07416994Carcinoma, Non-Small-Cell Lung · China3RecruitingMediLink Therapeutics (Suzhou)Aug 31, 2028440
NCT07202364Carcinoma, Non-Small-Cell Lung · China2RecruitingMediLink Therapeutics (Suzhou)Jan 31, 2027100
NCT07169994Breast Neoplasms · China2RecruitingMediLink Therapeutics (Suzhou)Sep 1, 2026414
NCT07111520Carcinoma, Non-Small-Cell Lung · United States, Australia, China and more2RecruitingBioNTechNov 2028880
NCT07070232Lethal Congenital Contracture Syndrome 2 · United States, Australia, Belgium and more2RecruitingBioNTechMar 20281,438
NCT06439771Breast Neoplasms · China2RecruitingMediLink Therapeutics (Suzhou)Jul 30, 2027180
NCT06107686Breast Neoplasms · China2RecruitingMediLink Therapeutics (Suzhou)Nov 2026200
NCT05653752Carcinoma, Non-Small-Cell Lung · United States, China1Active, not recruitingMediLink Therapeutics (Suzhou)Dec 202680

How it is read

Names in the registry

  • “YL202”, 4 entries
  • “BNT326”, 2 entries
  • “YL202 should be intravenously infused”, 2 entries
  • “YL202 for injection; Toripalimab injection”, 1 entry
  • “YL202 for injection; Furmonertinib Mesilate Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.